Industry Spotlight

Dimerix requests pre-IND meeting with FDA

28 April via Biotech Dispatch: Dimerix (ASX:DXB), a clinical-stage biotechnology company focussed on discovering and developing new therapeutic treatments identified using its proprietary screening assay, has announced that it has filed a request to the US FDA for a ... | READ MORE

CSL marks official centenary

26 April 2016 via Biotech Dispatch: "CSL may be one hundred years old but we are just getting started,” according to CEO Mr Paul Perreault. Established in 2016 as the government-owned Commonwealth Serum Laboratories, CSL was to ensure Australia had reliable ac... | READ MORE

Opthea announces positive result for OPT-302

22 April 2016 via Biotech Dispatch: Melbourne-based Opthea (ASX:OPT), a developer of biologic therapies for the treatment of eye diseases, has successfully met the primary objective of safety in the dose escalation of its ongoing first-in-human clinical trial of OPT-... | READ MORE

Time expires on R and R tax cut but concerns remain

22 April 2106 via Biotech Dispatch: Time has effectively expired on the Governments legislation that would cut claims under the R&D Tax Incentive but the proposal remains on the table, with less than two weeks until the Budget. The Government is currently reviewing ... | READ MORE

Viralytics reports data from three studies

20 April 2016 via Biotech Dispatch: Viralytics (ASX:VLA) has announced that abstracts for all three posters for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2016 have been publicly released. The first presentation included early... | READ MORE

CSL announces R and D support program

20 April 2016 via Biotech Dispatch: CSL has created a new $25 million fellowship program designed to support early stage and translational research in Australia. The CSL Centenary Fellowships will be available to Australian researchers seeking to consolidate their c... | READ MORE

Treasury confirms MRFF funding hole

15 April via Biotech Dispatch: The Medical Research Future Fund will reach its $20 billion target 12 months late unless the Government secures parliamentary support for its proposed increase in PBS patient co-payments and safety net thresholds. According to Treasury... | READ MORE

FDA approves IDT brain cancer drug

15 April 2016 via Biotech Dispatch: ;IDT Australia (ASX:IDT) has announced FDA approval of its oral brain cancer drug Temozolomide. The approval, which triggered a significant jump in the companys share price, will pave the way for the commercial launch of what is t... | READ MORE

Admedus expands distribution partnership with CORONEO

13 April 2016 via Biotech Dispatch: Admedus (ASX:AHZ) has expanded its exclusive distribution partnership with CORONEO to sell its Extra-Aortic Annuloplasty Ring and related products in Australia and New Zealand. Admedus said it anticipates gaining marketing approva... | READ MORE

Not enough being done to 'stimulate' medical innovation

13 April 2016 via Biotech Dispatch: More needs to be done to stimulate investment in medical research, according to the official communiqué of the Council of Australian Governments Health Council. The Council met in Perth late last week to discuss a range of ... | READ MORE

Previous page | Next page
Jump to page